Scholarlink

<p>We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 cancer patients, to discover clinical and molecular determinants that predispose cancer patients to breakthrough infections. Patients with B cell malignancies, with differential expression of <i>CD24</i>, <i>CDK14</i> and <i>PLEKHG1</i>, were most susceptible to breakthrough infections, suggesting that these patients may require more booster immunisations to ameliorate cellular responses and immune protection against COVID-19.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月9日

查看全文
  • Youjia Zhong,
  • Jiaqi Li,
  • Ainsley Ryan Yan Bin Lee,
  • Janice Yu Jin Tan,
  • Carina Jing Xuan Tay,
  • Clara WT Koh,
  • Ethan Yong Tzi Seow,
  • Wee Chee Yap,
  • Shi Yin Wong,
  • Chun En Yau,
  • Chen Ee Low,
  • Kelvin Bryan Tan,
  • Barnaby Edward Young,
  • Yan Su,
  • Arun George Devasia,
  • Perumal Dharuman,
  • Alexander Lezhava,
  • Rahul Pandey,
  • Panneer Selvi Govindaraju,
  • Sidney Yee,
  • Ruifen Weng,
  • Candy Khoo,
  • Shaun Shi Yan Tan,
  • Matilda Lee,
  • Joline Lim,
  • Esther Chan,
  • Carol LF Ho,
  • Louis Yi Ann Chai,
  • Chee Wah Tan,
  • Soo Chin Lee,
  • Kuan Rong Chan,
  • Raghav Sundar

摘要

We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 cancer patients, to discover clinical and molecular determinants that predispose cancer patients to breakthrough infections. Patients with B cell malignancies, with differential expression of CD24, CDK14 and PLEKHG1, were most susceptible to breakthrough infections, suggesting that these patients may require more booster immunisations to ameliorate cellular responses and immune protection against COVID-19.